Xiap Deficiency clinical trials

Explore recruiting xiap deficiency clinical trials.

Recruiting xiap deficiency studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Xiap Deficiency trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A three-period multicenter study, with a randomized-withdrawal, double-blinded, placebo-controlled design to evaluate the clinical efficacy, safety and tolerability of MAS825 in patients with monogenic IL-18 driven autoinflammatory diseases, including NLRC4-GOF, XIAP deficiency, or CDC42 mutations.

France, Spain, Czechia, Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

Open-label extension study with Tadekinig alfa (r-hIL-18BP) to monitor safety and tolerability in patients with IL-18 driven monogenic autoinflammatory conditions: NLRC4 mutation and XIAP deficiency

Germany

Therapeutic confirmatory (Phase III) EU CTIS Study details

Xiap Deficiency trials by city

Xiap Deficiency in Toronto Xiap Deficiency in Vancouver Xiap Deficiency in Montreal Xiap Deficiency in Calgary Xiap Deficiency in Edmonton Xiap Deficiency in Ottawa Xiap Deficiency in Winnipeg Xiap Deficiency in Quebec City Xiap Deficiency in Hamilton Xiap Deficiency in Kitchener Xiap Deficiency in London Xiap Deficiency in Halifax Xiap Deficiency in New York Xiap Deficiency in Los Angeles Xiap Deficiency in Chicago Xiap Deficiency in Houston